Citta Pharmaceuticals is categorized under Research and Development Laboratories in New York City, NY and active since 2011.
Citta Pharmaceuticals was established in 2011, and today employs 1 to 4, earning Unknown per year. This is a Research and Development Laboratories business, which does work in the B2B market, and is classified as a Research and Development Laboratories, under code number 541712 by the NAICS.
If you are seeking more information, feel free to contact Ottavio Arancio at the company’s single location by writing to 2700 Broadway Apartment 5h, New York City, New York NY 10025 or by phoning (646) 209-1335. You can also visit this business on Facebook by going to their profile page at Facebook or on find them on Twitter.
| Business Name: | Citta Pharmaceuticals |
| Contact Person: | Ottavio Arancio |
| Address: | 2700 Broadway Apartment 5h, New York City, New York 10025 |
| Phone Number: | (646) 209-1335 |
| Annual Revenue (USD): | Unknown |
| Founded: | 2011 |
| Location Type: | Single Location |
| Employee Number: | 1 to 4 |
| Business Type: | B2B (Business to Business) |
| Business Category: | Research and Development Laboratories |
| SIC Code: | 8731 |
| NAICS Code: | 541712 |
| Share This Business: |
Citta Pharmaceuticals was started in 2011 to provide professional Research and Development Laboratories under the SIC code 8731 and NAICS code 541712. Since its inception, the company has gone on to take a total of 1 to 4 personnel under its employment and has achieved earnings of Unknown per annum.
Feel free to contact Ottavio Arancio for inquiries that concern Citta Pharmaceuticals by calling the company number (646) 209-1335, as your correspondence is most welcome. Additionally, the physical location of the single location of Citta Pharmaceuticals can be found at the coordinates 40.799138,-73.968226 as well as the street address 2700 Broadway Apartment 5h in New York City, New York 10025.
For its online presence, you may visit Citta Pharmaceuticals’s website at and engage with its social media outlets through on Twitter and on Facebook.